Login to Your Account

Roche Wooing Biomarin or Is It Floating Another Trial Balloon?

By Marie Powers
Staff Writer

Friday, September 20, 2013
Shares of Biomarin Pharmaceutical Inc. topped $80 Thursday morning, one day after hitting a previous 52-week high. Although the stock (NASDAQ:BMRN) lost some lift late in the day, closing up 90 cents at $78.39, the uptick still pushed the company’s market cap to $11 billion.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription